Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
96.5M
-
Number of holders
-
176
-
Total 13F shares, excl. options
-
73.4M
-
Shares change
-
+6.63M
-
Total reported value, excl. options
-
$962M
-
Value change
-
+$83.1M
-
Put/Call ratio
-
1.42
-
Number of buys
-
101
-
Number of sells
-
-62
-
Price
-
$13.12
Significant Holders of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) as of Q3 2024
215 filings reported holding AVDL - AVADEL PHARMACEUTICALS PLC - Common Stock as of Q3 2024.
AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) has 176 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.4M shares
of 96.5M outstanding shares and own 76.04% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (13.3M shares), GENDELL JEFFREY L (5.81M shares), BlackRock, Inc. (5.26M shares), Polar Capital Holdings Plc (4.83M shares), VANGUARD GROUP INC (3.86M shares), BRAIDWELL LP (3.39M shares), Vivo Capital, LLC (2.68M shares), CITADEL ADVISORS LLC (2.36M shares), Two Seas Capital LP (2.25M shares), and WEALTH EFFECTS LLC (2.23M shares).
This table shows the top 176 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.